---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-311027"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2022-12-22T23:59:59+00:00"
generated_at: "2026-06-21T00:10:53.153181+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# CEO RA Session II resigns; Chairman Sean Nolan appointed CEO; Sukumar Nagendran named President and Head of R&D

## Summary
- RA Session II resigned as President and CEO effective Dec 16, 2022; remains on Board.
- Sean Nolan (Chairman) appointed CEO immediately; compensation not yet finalized.
- Sukumar Nagendran, M.D., appointed President and Head of R&D; Suyash Prasad becomes Chief Medical Officer.
- Company will file separation terms later; compensation for Nolan and Nagendran to be amended.
- Company to host investor call mid-January after FDA Type B meeting on GAN program.

## SEC filing metadata
- accession: 0001193125-22-311027
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2022-12-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312522311027/0001193125-22-311027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312522311027/d398679d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-311027
- JSON: https://secwatch.observer/filing/0001193125-22-311027.json
- Plain text: https://secwatch.observer/filing/0001193125-22-311027.txt

## Key facts
- Executive change
  Suyash Prasad changed role as Chief Medical Officer at Taysha Gene Therapies, Inc..
  - Action: title changed
  - Role: Chief Medical Officer
  source text: Dr. Suyash Prasad’s title was changed from Chief Medical Officer and Head of Research and Development to Chief Medical Officer, effective as of Dr. Nagendran’s appointment.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312522311027/0001193125-22-311027-index.htm
- Executive change
  Sean Nolan was appointed as Chief Executive Officer at Taysha Gene Therapies, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On December 16, 2022, the Board appointed Sean Nolan as the Company’s Chief Executive Officer, effective as of the effective time of Mr. Session’s resignation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312522311027/0001193125-22-311027-index.htm
- Executive change
  Sukumar Nagendran was appointed as President and Head of Research and Development at Taysha Gene Therapies, Inc..
  - Action: appointed
  - Role: President and Head of Research and Development
  source text: On December 16, 2022, the Board appointed Dr. Sukumar Nagendran as the Company’s President and Head of Research and Development, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312522311027/0001193125-22-311027-index.htm
- Executive change
  RA Session II resigned as President and Chief Executive Officer at Taysha Gene Therapies, Inc..
  - Action: resigned
  - Role: President and Chief Executive Officer
  source text: On December 16, 2022, RA Session II, the President and Chief Executive Officer of Taysha Gene Therapies, Inc. (the “ Company ”), resigned from his operating role, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312522311027/0001193125-22-311027-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.